about
Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials.Radiological features and pathological-biological correlations in 348 women with breast cancer under 35 years old.The oncologic outcome and immediate surgical complications of lipofilling in breast cancer patients: a multicenter study--Milan-Paris-Lyon experience of 646 lipofilling procedures.Immediate breast reconstruction after mastectomy.Comparison of Treatment Outcome Between Invasive Lobular and Ductal Carcinomas in Patients Receiving Partial Breast Irradiation With Intraoperative Electrons.Improved prognosis of young patients with breast cancer undergoing breast-conserving surgery.CDH1 germline mutations and hereditary lobular breast cancer.BRCA1/2 germline missense mutations: a systematic review.Ipsilateral axillary recurrence after breast conservative surgery: The protective effect of whole breast radiotherapy.Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study.Incidence, predictive factors, and prognosis for winged scapula in breast cancer patients after axillary dissection.Nipple-sparing and skin-sparing mastectomy: Review of aims, oncological safety and contraindications.The Veronesi quadrantectomy: an historical overview.Surgical treatment of breast lesions at a Day Centre: Experience of the European Institute of Oncology.Oncoplastic Breast-Conserving Surgery for Tumors Larger than 2 Centimeters: Is it Oncologically Safe? A Matched-Cohort Analysis.Angiosarcoma and atypical vascular lesions of the breast: diagnostic and prognostic role of MYC gene amplification and protein expression.Outcome and Medial Presentation of Breast Cancer: European Institute of Oncology Experience.Poly implant prothèse asymmetrical anatomical breast implants: a product recall study.Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer.Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer.Sentinel node biopsy in patients with previous breast aesthetic surgery.Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy.A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer.Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation.Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase.Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.Axillary web syndrome self-assessment questionnaire: Initial development and validation.Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients.Sarcoma of the breast: outcome and reconstructive options.Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer.The effects of a multimodal training program on burnout syndrome in gynecologic oncology nurses and on the multidisciplinary psychosocial care of gynecologic cancer patients: an Italian experience.A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer.Outcome of male breast cancer: a matched single-institution series.Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.Conservative mastectomy versus nipple-sparing mastectomy: preliminary considerations of oncological safety on 30 patients not receiving intra-operative radiotherapy.From the maximum tolerable to the minimum effective treatment: The Umberto Veronesi's life commitment to breast cancer care.Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement.
P50
Q35611834-E0055BB2-A9BC-42FF-81ED-90EDF138C542Q36490712-97BF341F-A52D-48B7-A151-E6E856B15152Q37866617-45D24711-D1B1-4A1B-BCD4-D798C1FCDB78Q37947883-5FBA1C8C-3157-4472-BCD3-E3D8EE5E0546Q38620697-765D6845-8BAF-4838-B2DA-D57EC2705A11Q38632744-D15F6979-E092-490D-822D-37E4F169CF68Q38694163-86279569-8866-4E72-9394-9AEFB20AA927Q38918189-57A43E95-E36B-4CBC-B87C-4A29FB22B06DQ39034293-168790C1-3BFD-4871-99D3-4CC9BA7B564AQ39219014-40360E48-868E-490F-B769-09DB9BF12368Q39257137-1269F396-8EC5-4EFA-9A39-3F468A341407Q39412117-ECF666EB-7A5B-4AC1-84F3-E37FAFB1AB29Q39424585-EF80FE61-B42F-4F6C-AC42-3A593A95098FQ39814198-86F0FE35-C952-4979-A5D9-7ADA7E528114Q40932624-2A7CDBC0-5908-4A6A-806D-639061914A3EQ41040499-12F175D7-60A6-48C5-A534-24223796C2D5Q41500814-735F8D1D-D07E-45DA-ADA9-6D6204E1C856Q41651665-718B3824-D0BC-4682-B7E9-01428B4CB521Q42781340-3B081153-6C83-4D1E-90D1-C3388E71073EQ43062601-1EC24B1C-B610-4034-936A-F175609AD604Q43120755-CAE44F52-D527-4DD1-89CC-1A0484A3F61AQ43532276-17D12F61-1897-4828-84EF-F0FE42143DEDQ44100959-08799A79-AB77-4E9C-816A-46FDC3B335C3Q44393496-0F2A5CF0-87A4-4FFF-9F1C-8AD664414F10Q44543667-E38630AD-FE39-411F-8FB0-EE4BA4200F96Q44592596-4585C781-E8E9-45E9-B917-2FAEE49DC307Q44808662-D373D1EA-E4A7-409F-8B35-8BEF0F9B0427Q45019549-B8E2B959-9A57-413F-AECA-93568AC1CF1DQ45022438-D264D008-C63C-4F63-99F0-8D5E63FD47DBQ45406902-D58A089C-20AF-4CF5-9C21-2D62985EA5C2Q45614106-99C42C5E-D1A9-4FAD-AB36-075A3BBAD63DQ45928603-64D3940A-5C1C-4EF6-8B39-E74A14F2C95FQ45953263-FC853E48-FA96-4F15-AACF-6308AEB0632EQ46134834-384B3024-BD48-4E7E-9BDC-EA89FD95C5A2Q46138991-58A3789A-8494-4A88-BE39-C1D3F385773DQ46862276-9574A835-6D22-4959-8FFD-2F8CE7EF4C0AQ46911956-C1E429CF-6651-4E35-9B5C-010243B81DD6Q47142700-E27F935D-4EFB-406F-AE08-FD57AD428097Q47369720-CF7F43DC-9D6B-4B33-9ABA-D1E0B8084467Q47390449-26D56EAE-F6ED-4BE4-8BDB-6BDB018CEC98
P50
description
onderzoeker
@nl
researcher ORCID: 0000-0001-8926-4106
@en
name
Paolo Veronesi
@ast
Paolo Veronesi
@en
Paolo Veronesi
@es
Paolo Veronesi
@nl
type
label
Paolo Veronesi
@ast
Paolo Veronesi
@en
Paolo Veronesi
@es
Paolo Veronesi
@nl
prefLabel
Paolo Veronesi
@ast
Paolo Veronesi
@en
Paolo Veronesi
@es
Paolo Veronesi
@nl
P106
P31
P496
0000-0001-8926-4106